Since insulin resistance is a distinctive feature of both steatohepatitis and AD, some studies have proposed the use of insulin-sensitizing agents, such as PPAR agonists, that are able to activate insulin-responsive genes and their signaling pathways to treat liver and brain insulin resistance-mediated diseases [66]. Here, PPARA is linked to Insulin resistance.